缬沙坦对动脉粥样硬化患者CRP的影响(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 探讨缬沙坦抑制C反应蛋白(CRP)的效果与机制及其在动脉粥样硬化临床中的价值。 方法 对本院2009～2012年收治的100例动脉粥样硬化患者平均分为治疗组和对照组，治疗组采用缬沙坦治疗。分别测量患者治疗前外周血血清中的CRP和治疗后血清中的CRP，对比两组血清中治疗前和治疗后CRP含量的变化。 结果 治疗组治疗前和治疗后血清中CRP的含量分别为4.87、2.58 mg/L，变化较大，治疗前后差异有统计学意义(P < 0.05)。对照组治疗前后血清中的CRP含量分别为4.84、3.78 mg/L，变化较大，治疗前后差异有统计学意义(P < 0.05)。治疗组与对照组治疗后差异无统计学意义(P > 0.05)。 结论 动脉粥样硬化可能与炎症有关，缬沙坦可以抑制动脉粥样患者炎性因子的释放，从而降低CRP的水平。CRP作为一种动脉粥样硬化检测的指标具有可行性。
[关键词] 缬沙坦；C反应蛋白；动脉粥样硬化；指标
[中图分类号] R972+.6 [文献标识码] A [文章编号] 1674-4721(2012)07(a)-0088-02
The affect of valsartan on CRP in atherosclerosis patients
LU Huilan
5712 Aircraft Repair Plant Workers' Hospital, Hunan Province, Changsha 410000, China
[Abstract] Objective To explore the effects and mechanism of valsartan on inhibiting CRP and its clinical value of atherosclerosis. Methods One hundred atherosclerosis patients addmitted from 2009 to 2012 were divided into treatment group and control group, the treatment group were given valsartan. The plasma CRP concentration of the two groups at pre-treat and post-treat were measured and were compared, respectively. Results The CRP concentration of treatment group at pre-treat and post-treat was 4.87 mg/L and 2.58 mg/L, respectively, the difference was significant (P < 0.05). The control group was 4.84 mg/L and 3.78 mg/L, the difference was significant (P < 0.05). The difference between treatment group and control group at post-treat was not significant (P > 0.05). Conclusion Atherosclerosis may be relate to inflamation, and valsartan can inhibit the release of inflamator and decrease the levels of CRP. As a marker of atherosclerosis, CRP is feasible.
[Key words] Valsatan; C-reactive protein; Atherosclerosis; Marker
动脉粥样硬化(atherosclerosis，AS)是一个缓慢而复杂的病理过程，炎症反应贯穿这一过程的始终。研究表明血管紧张素(AngⅡ)的致炎作用参与AS的发病机制，主要是通过血管紧张素1型受体(AT1R)介导。C反应蛋白(C-reactive protein ......
您现在查看是摘要介绍页，详见PDF附件(2188kb)。